Get the Stockscreener App
18.90
1.61%
0.30
Yarrow Bioscience, Inc. Common Stock stock is traded at $18.90, with a volume of 105.57K.
It is up +1.61% in the last 24 hours and down -25.88% over the past month.
See More
Previous Close:
$18.60
Open:
$18.56
24h Volume:
105.57K
Relative Volume:
1.09
Market Cap:
$159.50M
Revenue:
Net Income/Loss:
P/E Ratio:
-
EPS:
-
Net Cash Flow:
1W Performance:
-4.88%
1M Performance:
-25.88%
6M Performance:
+0.00%
1Y Performance:
+0.00%
1-Day Range:
$0.00
$0.00
1-Week Range:
$18.16
$20.94
52-Week Range:
$18.16
$44.28
Yarrow Bioscience, Inc. Common Stock Stock (YARW) Company Profile
Name
Yarrow Bioscience, Inc. Common Stock
Sector
Industry
Phone
-
Address
-
Compare YARW vs VRTX, MRNA, REGN, ARGX, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
YARW
Yarrow Bioscience, Inc. Common Stock
|
18.90 | 159.50M | 0 | 0 | 0 | 0.00 |
VRTX
Vertex Pharmaceuticals Inc
|
507.65 | 128.67B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
238.98 | 95.41B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
799.43 | 82.31B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
851.86 | 53.57B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
374.28 | 42.34B | 5.76B | 514.49M | 1.10B | 4.4813 |
Yarrow Bioscience, Inc. Common Stock Stock (YARW) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-03-26 | Initiated | BTIG Research | Buy |
| Jul-31-25 | Downgrade | BTIG Research | Buy → Neutral |
| Nov-18-24 | Initiated | BTIG Research | Buy |
| Dec-06-21 | Resumed | H.C. Wainwright | Buy |
Yarrow Bioscience, Inc. Common Stock Stock (YARW) Latest News
A passive investor reports ownership of 1 million Yarrow Bioscience (YARW) shares. - Stock Titan
Raymond Debbane Reports 675,000 Shares in Yarrow Bioscience (NASDAQ: YARW) Representing 7.2% Passive Stake - Kalkine Media
New investor group tops 5% in Yarrow Bioscience (YARW) - Stock Titan
Yarrow Bioscience (NASDAQ: YARW) Grants Underwriters 30-Day Option for 865,384 Additional Shares - Kalkine Media
Yarrow Bioscience Raises About $161.8 Million in Public Stock Offering at $26 Per Share - TradingView
Yarrow Bioscience Files Prospectus for 25.78 Million Warrant-Linked Shares Offering (NASDAQ: YARW) - Kalkine Media
Yarrow Bioscience launches public offering of common stock - Investing.com India
Yarrow Bioscience Launches Public Offering of Common Stock - Yahoo Finance
Yarrow Bioscience Announces Pricing of $150 Million Underwritten Public Offering - Business Wire
Yarrow Bioscience prices $150M public offering at $26/share - Investing.com
Yarrow Bioscience Announces Proposed Underwritten Public Offering - Business Wire
YARW SEC FilingsYarrow Bioscience, Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
Yarrow Bioscience Reports Second Quarter 2026 Financial Results and Provides Business Update - Yahoo Finance
Yarrow Bioscience Reports Second Quarter 2026 Financial Results and Provides Business Update - Business Wire
Yarrow Bioscience Reports Second Quarter 2026 Financial Results and Provides Business Update - BioSpace
OrbiMed Advisors Discloses Investment at Yarrow Bioscience with 9.97% Stake - TradingView
Yarrow Bioscience Alters Capital Structure With Warrant Exchange - TipRanks
Yarrow Bioscience, Inc. (YARW) Company Information - Simply Wall Street
Yarrow Bioscience (Nasdaq:YARW)Stock Analysis - Simply Wall Street
Yarrow Bioscience Completes VYNE Merger and Nasdaq Debut - TipRanks
Yarrow Bioscience Completes VYNE Merger and $200 Million Private Financing - citybiz
Yarrow Bioscience Announces Closing of Merger with VYNE Therapeutics and Initiation of Dosing in Phase 2a/2b Trial of YB-101, a Potential First-in-Class Treatment for Graves’ Disease and Thyroid Eye Disease - Yahoo Finance
VYNE Therapeutics Provides Update Regarding Cash Dividend, Reverse Stock Split and Anticipated Timing of Closing of the Proposed Merger with Yarrow Bioscience - Yahoo Finance
VYNE Therapeutics Announces 1-for-50 Reverse Stock Split, $17.3M Special Dividend, and Merger with Yarrow Bioscience – Minichart - Minichart
VYNE Sets $17.3M Cash Dividend Before Expected Yarrow Merger - Stock Titan
VYNE Therapeutics Announces 1-for-50 Reverse Stock Split and Provides Update Regarding Special Dividend in Connection with the Proposed Merger with Yarrow Bioscience - Yahoo Finance
VYNE Therapeutics and Yarrow Bioscience Announce Merger to Advance YB-101 for Graves' Disease and Thyroid Eye Disease - Quiver Quantitative
New biotech merger backs antibody targeting Graves’ and thyroid eye disease - Stock Titan
Yarrow Bioscience, Inc. Common Stock Stock (YARW) Financials Data
There is no financial data for Yarrow Bioscience, Inc. Common Stock (YARW). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
1.69%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):